Ravi Madan, MD, Discusses Key Findings Utilizing PET Imaging and Tc99 Scans in Conjunction With Enzalutamide in mCRPC

Article

Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide

At the 2021 European Society for Medical Oncology Annual Congress, CancerNetwork® spoke with Ravi A. Madan, MD, clinical director of the genitourinary malignancies branch at the Center for Cancer Research, National Cancer Institute, about key findings from a clinical trial (NCT01867333) utilizing PET imaging and paired technetium (Tc99) scans in patients with metastatic castration-resistant prostate cancer who are undergoing treatment with enzalutamide (Xtandi).

Transcript:

The key highlights of this research in the context of 1 big finding [that wasn’t] surprising [was that] we did a pretty good job of helping patients understand that staying on [drug] until radiographic progression was an important way of optimizing and really getting all the benefit you can out of enzalutamide. In a separate analysis that we previously presented, which isn't probably too surprising to people who use the drug, is that on average, [patients on] enzalutamide patients had a first [prostate-specific antigen] rise at 6 months but radiographic progression didn't occur until 23 months. That gave us an opportunity in the interim to evaluate what was going on [in] the sodium fluoride PET scans.

What we saw in this population that was treated with enzalutamide and immunotherapy...was that even though patients had stable disease on the Tc99 scans and were still deriving clinical benefit in terms of stable symptoms, a lot was going on [with] the Tc99 scans. But not all of that represented progression of disease, which, if they only got 1 or 2 scans, at certain intervals, it could have been misinterpreted. What we saw was, among these 18 patients [was] nearly 400 new lesions appear on the sodium fluoride scans, nearly 28% of [which] actually resolved over time. [Therefore], they weren't representing clinically relevant progressive disease, in my opinion. Of the 18 patients, 14 had lesions that appeared and disappeared despite stable technetium scans. One of the important takeaways is that even though you're seeing what could be considered new lesions or findings on a platform like sodium fluoride, it may not represent treatment failure.

Reference

Madan RA, Gandhy SU, Bilusic M, et al. Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide. Presented at the 2021 European Society for Medical Oncology Annual Congress; September 16-21, 2021; virtual. Abstract 605P.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content